Should I buy or sell Genmab A/S stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares. View GMAB analyst ratings or view top-rated stocks .

What is Genmab A/S's stock price target for 2024?

15 brokers have issued 12-month target prices for Genmab A/S's stock. Their GMAB share price targets range from $23.00 to $54.00. On average, they expect the company's share price to reach $41.60 in the next year. This suggests a possible upside of 28.9% from the stock's current price. View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts .

How have GMAB shares performed in 2023?

Genmab A/S's stock was trading at $42.38 at the start of the year. Since then, GMAB shares have decreased by 23.8% and is now trading at $32.28. View the best growth stocks for 2023 here .

Are investors shorting Genmab A/S?

Genmab A/S saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 1,530,000 shares, a decrease of 15.9% from the October 31st total of 1,820,000 shares. Based on an average trading volume of 785,500 shares, the short-interest ratio is currently 1.9 days. View Genmab A/S's Short Interest .

When is Genmab A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our GMAB earnings forecast .

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) released its quarterly earnings results on Tuesday, November, 7th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.34 by $0.13. Genmab A/S had a trailing twelve-month return on equity of 15.03% and a net margin of 25.54%.

What ETFs hold Genmab A/S's stock?

ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT) , iShares Biotechnology ETF (IBB) , Goldman Sachs Future Health Care Equity ETF (GDOC) , B.A.D. Etf (BAD) , Range Cancer Therapeutics ETF (CNCR) and WisdomTree BioRevolution Fund (WDNA) . ActivePassive International Equity ETF (APIE) .

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA) , Alibaba Group (BABA) , Johnson & Johnson (JNJ) , CVS Health (CVS) , Home Depot (HD) , Intel (INTC) , Pfizer (PFE) , PayPal (PYPL) , Verizon Communications (VZ) and Cisco Systems (CSCO) .

When did Genmab A/S IPO?

(GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (0.37%), Morgan Stanley (0.17%), Envestnet Asset Management Inc. (0.14%), Royal Bank of Canada (0.13%), Stifel Financial Corp (0.11%) and Hardman Johnston Global Advisors LLC (0.09%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Genmab A/S Stock Price, News & Analysis (NASDAQ:GMAB)

$32.28

-0.08 (-0.25%)

(As of 12/8/2023 ET)

Compare

Today's Range: $32.16
▼
$32.65
50-Day Range: $27.94
▼
$35.44
52-Week Range: $27.74
▼
$47.12

Volume: 301,205 shs
Average Volume: 570,086 shs
Market Capitalization: $21.33 billion

P/E Ratio: 34.34
Dividend Yield: N/A
Price Target: $41.60

Genmab A/S MarketRank™ Stock Analysis

Analyst Rating: Hold
2.47 Rating Score
Upside/Downside: 28.9% Upside
$41.60 Price Target
Short Interest: Healthy
0.23% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.52
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 2.52%
From $1.19 to $1.22 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

83rd out of 954 stocks

Pharmaceutical Preparations Industry

15th out of 362 stocks

4.2

Analyst's Opinion

Consensus Rating
Genmab A/S has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 9 buy ratings, 4 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.60, Genmab A/S has a forecasted upside of 28.9% from its current price of $32.28.
Amount of Analyst Coverage
Genmab A/S has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.23% of the outstanding shares of Genmab A/S have been sold short.
Short Interest Ratio / Days to Cover
Genmab A/S has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Genmab A/S has recently decreased by 15.93%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Genmab A/S does not currently pay a dividend.
Dividend Growth
Genmab A/S does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GMAB.

3.1

News and Social Media Coverage

News Sentiment
Genmab A/S has a news sentiment score of 1.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Genmab A/S this week, compared to 3 articles on an average week.
Search Interest
6 people have searched for GMAB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genmab A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.54% of the stock of Genmab A/S is held by insiders.
Percentage Held by Institutions
Only 6.29% of the stock of Genmab A/S is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Genmab A/S are expected to grow by 2.52% in the coming year, from $1.19 to $1.22 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Genmab A/S is 34.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.61.
Price to Earnings Ratio vs. Sector
The P/E ratio of Genmab A/S is 34.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.41.
Price to Earnings Growth Ratio
Genmab A/S has a PEG Ratio of 2.02. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Genmab A/S has a P/B Ratio of 5.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Genmab A/S Stock (NASDAQ:GMAB)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GMAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GMAB Stock News Headlines

December 8, 2023 | americanbankingnews.com

Genmab A/S (NASDAQ:GMAB) Rating Increased to Buy at UBS Group

November 29, 2023 | americanbankingnews.com

Genmab A/S (NASDAQ:GMAB) Given "Buy" Rating at HC Wainwright

December 8, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 28, 2023 | markets.businessinsider.com

9 Analysts Have This to Say About Genmab

November 27, 2023 | finance.yahoo.com

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

November 14, 2023 | morningstar.com

Genmab A/S GMAB

November 8, 2023 | markets.businessinsider.com

BTIG Analyst Rates Genmab as ‘Buy’ Citing Solid Financials and Strategic Growth Moves

November 7, 2023 | seekingalpha.com

Genmab A/S 2023 Q3 - Results - Earnings Call Presentation

December 8, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

November 2, 2023 | finance.yahoo.com

GMAB Nov 2023 45.000 call

November 1, 2023 | msn.com

Genmab - ADR (GMAB) Price Target Increased by 32.76% to 181.55

October 18, 2023 | markets.businessinsider.com

Robust Sales and Financial Position Lead to Buy Rating for Genmab: An Analysis of Ram Selvaraju’s Recommendation

September 26, 2023 | msn.com

AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL

September 25, 2023 | businesswire.com

EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or ...

September 5, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Genmab (GMAB)

September 5, 2023 | markets.businessinsider.com

Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications

September 5, 2023 | finance.yahoo.com

Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals

September 5, 2023 | finance.yahoo.com

Why Shares of Zai Lab Limited Were Jumping on Tuesday

September 4, 2023 | reuters.com

Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint

August 31, 2023 | msn.com

Denmark stocks lower at close of trade; OMX Copenhagen 20 down 1.55%

August 30, 2023 | seekingalpha.com

Genmab Is Down To Attractive Levels

August 15, 2023 | markets.businessinsider.com

Analyst Expectations for Genmab's Future

August 9, 2023 | markets.businessinsider.com

Genmab (GMAB) Receives a Buy from Truist Financial

July 28, 2023 | finanznachrichten.de

Genmab A/S: Genmab Updates 2023 Financial Guidance

July 28, 2023 | seekingalpha.com

Genmab raises FY 2023 guidance on back of Darzalex sales

July 24, 2023 | markets.businessinsider.com

12 Analysts Have This to Say About Genmab

July 21, 2023 | finance.yahoo.com

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

See More Headlines

Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GMAB
CUSIP: N/A
CIK: 1434265
Web: www.genmab.com
Phone: (457) 020-2728
Fax: N/A
Employees: 1,660
Year Founded: 1999

Price Target and Rating

Average Stock Price Target: $41.60
High Stock Price Target: $54.00
Low Stock Price Target: $23.00
Potential Upside/Downside: +29.1%
Consensus Rating: Hold
Rating Score (0-4): 2.47
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.94
Trailing P/E Ratio: 34.29
Forward P/E Ratio: 27.08
P/E Growth: 2.02
Net Income: $781.91 million
Net Margins: 25.54%
Pretax Margin: 32.55%
Return on Equity: 15.03%
Return on Assets: 13.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.38
Quick Ratio: 11.36

Sales & Book Value

Annual Sales: $17.02 billion
Price / Sales: 1.25
Cash Flow: $1.27 per share
Price / Cash Flow: 25.31
Book Value: $5.89 per share
Price / Book: 5.47

Miscellaneous

Outstanding Shares: 660,675,000
Free Float: 650,501,000
Market Cap: $21.29 billion
Optionable: Not Optionable
Beta: 1.01

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Jan G.J. van de Winkel Ph.D. (Age 62)
Co-Founder, President & CEO
Comp: $2.75M
Mr. Anthony Pagano (Age 45)
Executive VP & CFO
Comp: $1.02M
Mr. Anthony Mancini (Age 52)
Executive VP & COO
Comp: $1.11M
Mr. Martin Schultz (Age 47)
Senior Director of Clinical Operations & Non-Independent Director
Comp: $73.03k
Dr. Judith V. Klimovsky M.D. (Age 65)
Executive VP & Chief Development Officer
Comp: $1.15M
Dr. Tahamtan Ahmadi (Age 50)
Executive VP, Chief Medical Officer & Head of Experimental Medicines
Comp: $1.1M
Dr. Mijke Zachariasse Ph.D. (Age 49)
Senior Director, Head of Antibody Research Materials & Non-Independent Director
Comp: $146.05k
Mr. Takahiro Hamatani (Age 48)
Senior Director of Finance Japan & Non-Independent Director
Comp: $73.03k
Mr. Andrew Carlsen
Senior Director, VP & Head of Investor Relations
Ms. Birgitte Stephensen M.Sc. (Age 62)
Executive VP & Chief Legal Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Genmab A/S was last updated on Sunday, December 3, 2023 at 4:29 PM.

Pros

Here are some ways that investors could benefit from investing in Genmab A/S:

Genmab A/S has recently announced positive clinical trial results for its latest product, which has the potential to drive significant revenue growth.
The company has a strong pipeline of innovative drugs in development, which could lead to future blockbuster products and increased market share.
Genmab A/S has a solid financial position with a healthy balance sheet and strong cash flow, providing stability and potential for future investments and acquisitions.
The company has a track record of successful collaborations with major pharmaceutical companies, which could lead to additional partnership opportunities and revenue streams.
Genmab A/S has a strong management team with extensive experience in the biopharmaceutical industry, providing confidence in the company's ability to execute its strategic plans.

Cons

Investors should be bearish about investing in Genmab A/S for these reasons:

The stock price of Genmab A/S has experienced significant volatility in recent periods, which may indicate higher risk and uncertainty for investors.
The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact the company's ability to bring new products to market and generate revenue.
Genmab A/S relies heavily on the success of its pipeline products, and any setbacks or failures in clinical trials could have a negative impact on the company's financial performance.
The company operates in a global market, and changes in international trade policies or geopolitical tensions could affect its operations and financial results.
Investing in biopharmaceutical companies carries inherent risks, including the potential for regulatory delays, patent expirations, and competition from generic drugs.

GMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings or view top-rated stocks.
What is Genmab A/S's stock price target for 2024?: 15 brokers have issued 12-month target prices for Genmab A/S's stock. Their GMAB share price targets range from $23.00 to $54.00. On average, they expect the company's share price to reach $41.60 in the next year. This suggests a possible upside of 28.9% from the stock's current price.
View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts.
How have GMAB shares performed in 2023?: Genmab A/S's stock was trading at $42.38 at the start of the year. Since then, GMAB shares have decreased by 23.8% and is now trading at $32.28.
View the best growth stocks for 2023 here.
Are investors shorting Genmab A/S?: Genmab A/S saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 1,530,000 shares, a decrease of 15.9% from the October 31st total of 1,820,000 shares. Based on an average trading volume of 785,500 shares, the short-interest ratio is currently 1.9 days.
View Genmab A/S's Short Interest.
When is Genmab A/S's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our GMAB earnings forecast.
How were Genmab A/S's earnings last quarter?: Genmab A/S (NASDAQ:GMAB) released its quarterly earnings results on Tuesday, November, 7th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.34 by $0.13. Genmab A/S had a trailing twelve-month return on equity of 15.03% and a net margin of 25.54%.

What ETFs hold Genmab A/S's stock?: ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Goldman Sachs Future Health Care Equity ETF (GDOC), B.A.D. Etf (BAD), Range Cancer Therapeutics ETF (CNCR) and WisdomTree BioRevolution Fund (WDNA).ActivePassive International Equity ETF (APIE).
What other stocks do shareholders of Genmab A/S own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).
When did Genmab A/S IPO?: (GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.
Who are Genmab A/S's major shareholders?: Genmab A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (0.37%), Morgan Stanley (0.17%), Envestnet Asset Management Inc. (0.14%), Royal Bank of Canada (0.13%), Stifel Financial Corp (0.11%) and Hardman Johnston Global Advisors LLC (0.09%).
How do I buy shares of Genmab A/S?: Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GMAB) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial